Journal of Clinical Oncology, Vol 18, Issue 7
(April), 2000: 1570-1593
© 2000 American Society for Clinical Oncology
Osteoporosis Due to Cancer Treatment: Pathogenesis and Management
By Johannes Pfeilschifter,
Ingo J. Diel
From the Berufsgenossenschaftliche Kliniken Bergmannsheil, Department of Internal Medicine, University of Bochum, Bochum, and Department of Obstetrics/Gynecology, University of Heidelberg, Heidelberg, Germany.
Address reprint requests to Prof Ingo J. Diel, MD, Department of Obstetrics/Gynecology, University Hospital, Voss-Str 9, D-69115 Heidelberg, Germany; email ingo_diel{at}med.uni-heidelberg.de
ABSTRACT
ABSTRACT: Many therapeutic regimens in cancer treatment carry the risk of causing or favoring the development of osteoporosis. Therapies in which hypogonadism may occur are most relevant in this respect. Prompt hormone replacement therapy is indicated in these patients. In patients in whom this is undesirable because of a hormone-dependent tumor, the risk of osteoporosis should be assessed by means of osteodensitometry, and prophylactic or therapeutic measures should be instituted if necessary. Early intervention improves outcome because osteoporosis therapy is most effective in preventing deterioration of bone mass. There remains much uncertainty in assessing the risk of combination chemotherapy with regard to the development of osteoporosis. Negative effects on the skeleton have, however, been demonstrated for individual drugs, such as methotrexate and ifosfamide. Negative effects of the tumor itself on bone metabolism may aggravate the degree of osteoporosis. Detailed data and long-term experience to assess the risk are urgently needed in this area and constitute an important research topic for the coming years and decades. This review discusses the most prevalent mechanisms of osteoporosis caused by cancer treatment and outlines therapeutic strategies for the prevention and treatment of therapy-induced bone loss.
This article has been cited by other articles:
|
|
|
|
 
S. L. Greenspan, A. Brufsky, B. C. Lembersky, R. Bhattacharya, K. T. Vujevich, S. Perera, S. M. Sereika, and V. G. Vogel
Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Clin. Oncol.,
June 1, 2008;
26(16):
2644 - 2652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Hadji
Menopausal symptoms and adjuvant therapy-associated adverse events
Endocr. Relat. Cancer,
March 1, 2008;
15(1):
73 - 90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Aapro, P. A. Abrahamsson, J. J. Body, R. E. Coleman, R. Colomer, L. Costa, L. Crino, L. Dirix, M. Gnant, J. Gralow, et al.
Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel
Ann. Onc.,
March 1, 2008;
19(3):
420 - 432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Wasilewski-Masker, S. C. Kaste, M. M. Hudson, N. Esiashvili, L. A. Mattano, and L. R. Meacham
Bone Mineral Density Deficits in Survivors of Childhood Cancer: Long-term Follow-up Guidelines and Review of the Literature
Pediatrics,
March 1, 2008;
121(3):
e705 - e713.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Body
Reply to Letter to the editor, by E. Yaman et al. (Ann Oncol)
Ann. Onc.,
February 1, 2008;
19(2):
398 - 398.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Brufsky
Cancer Treatment-Induced Bone Loss: Pathophysiology and Clinical Perspectives
Oncologist,
February 1, 2008;
13(2):
187 - 195.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Brown, S. P. Ellis, J. E. Lester, S. Gutcher, T. Khanna, O.-P. Purohit, E. McCloskey, and R. E. Coleman
Prolonged Efficacy of a Single Dose of the Bisphosphonate Zoledronic Acid
Clin. Cancer Res.,
September 15, 2007;
13(18):
5406 - 5410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. Goodman, W. Jiranek, E. Petrow, and A. W. Yasko
The Effects of Medications on Bone
J. Am. Acad. Ortho. Surg.,
August 1, 2007;
15(8):
450 - 460.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Bauer, T. D. Henning, D. Mueller, Y. Lu, S. Majumdar, and T. M. Link
Volumetric Quantitative CT of the Spine and Hip Derived from Contrast-Enhanced MDCT: Conversion Factors
Am. J. Roentgenol.,
May 1, 2007;
188(5):
1294 - 1301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Niinimaki, A. H. Harila-Saari, A. E. Jartti, R. M. Seuri, P. V. Riikonen, E. L. Paakko, M. I. Mottonen, and M. Lanning
High Body Mass Index Increases the Risk for Osteonecrosis in Children With Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
April 20, 2007;
25(12):
1498 - 1504.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. D. Dickerman
The Late Effects of Childhood Cancer Therapy
Pediatrics,
March 1, 2007;
119(3):
554 - 568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Greenspan, R. K. Bhattacharya, S. M. Sereika, A. Brufsky, and V. G. Vogel
Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
J. Clin. Endocrinol. Metab.,
January 1, 2007;
92(1):
131 - 136.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Brown, S. P. Ellis, P. Silcocks, A. Blumsohn, S. A. Gutcher, C. Radstone, B. W. Hancock, M. Q. Hatton, and R. E. Coleman
Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma.
Clin. Cancer Res.,
November 1, 2006;
12(21):
6480 - 6486.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Perez
Appraising Adjuvant Aromatase Inhibitor Therapy
Oncologist,
November 1, 2006;
11(10):
1058 - 1069.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Guise
Bone Loss and Fracture Risk Associated with Cancer Therapy
Oncologist,
November 1, 2006;
11(10):
1121 - 1131.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Michaud and S. Goodin
Cancer-treatment-induced bone loss, part 1
Am. J. Health Syst. Pharm.,
March 1, 2006;
63(5):
419 - 430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. E. Lonning, J. Geisler, L. E. Krag, B. Erikstein, Y. Bremnes, A. I. Hagen, E. Schlichting, E. A. Lien, E. S. Ofjord, J. Paolini, et al.
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer
J. Clin. Oncol.,
August 1, 2005;
23(22):
5126 - 5137.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Shapiro
Aromatase Inhibitors and Bone Loss: Risks in Perspective
J. Clin. Oncol.,
August 1, 2005;
23(22):
4847 - 4849.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S McCune, D. M Games, and J. L Espirito
Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors
Journal of Oncology Pharmacy Practice,
June 1, 2005;
11(2):
37 - 43.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. Lipton
Toward New Horizons: The Future of Bisphosphonate Therapy
Oncologist,
September 1, 2004;
9(suppl_4):
38 - 47.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Link, B. B. Koppers, T. Licht, J. Bauer, Y. Lu, and E. J. Rummeny
In Vitro and in Vivo Spiral CT to Determine Bone Mineral Density: Initial Experience in Patients at Risk for Osteoporosis
Radiology,
June 1, 2004;
231(3):
805 - 811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mandel, S. Atkinson, R. D. Barr, and P. Pencharz
Skeletal Morbidity in Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
April 1, 2004;
22(7):
1215 - 1221.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Gorlick, P. Anderson, I. Andrulis, C. Arndt, G. P. Beardsley, M. Bernstein, J. Bridge, N.-K. Cheung, J. S. Dome, D. Ebb, et al.
Biology of Childhood Osteogenic Sarcoma and Potential Targets for Therapeutic Development: Meeting Summary
Clin. Cancer Res.,
November 15, 2003;
9(15):
5442 - 5453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Rock and A. DeMichele
Nutritional Approaches to Late Toxicities of Adjuvant Chemotherapy in Breast Cancer Survivors
J. Nutr.,
November 1, 2003;
133(11):
3785S - 3793.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Strauss, J. T. Su, V. M. K. Dalton, R. D. Gelber, S. E. Sallan, and L. B. Silverman
Bony Morbidity in Children Treated for Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
June 15, 2001;
19(12):
3066 - 3072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
